News from Tuesday, September 5, 2023
Articles
SGLT2 Inhibitors, GLP-1 Receptor Agonists Linked to Reduced Risk for MACE
(9/5, Colby Stong, Cardiology Advisor) reports “Sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors are associated with decreased risk for major adverse cardiovascular events (MACE) compared with sulfonylureas, according to a study in The Lancet Diabetes & Endocrinology.” Full
New Initiative Will Bring Treatment of Depression into Dialysis Units
(9/1, Justin Cooper, Nephrology News & Issues) reports “A new initiative seeks to offer treatment for depression inside the dialysis clinic for patients with both conditions. The program will launch in February of 2024 across four states. Funded by a $2 million award from the Patient-Centered Outcomes Research Institute, the initiative will bring talk therapy and antidepressants into dozens of dialysis units, and then have clinicians take notes on how the process benefits patients.” Full
Value-Based Contracts Provide Options for State Medicaid Programs to Cover Gene Therapies
(9/1, Denise Myshko, Managed Healthcare Executive) reports “...The Centers for Medicare and Medicaid Services, [Magellan Rx’s Meredith Delk] pointed out, is moving away from unit costs to outcomes-based care, especially for high-cost therapies. ‘The reality is that Medicaid is required to cover many of these drugs if the therapy is deemed medically necessary for a patient.’” Full
Video: Dr Jordan Berlin Discusses Precision Medicine and Factoring Patient Preferences Into Treatment
(9/5, Brooke McCormick, The American Journal of Managed Care) “Jordan Berlin, MD, FASCO, of Vanderbilt University Medical Center (VUMC), discussed how physicians consider patient preferences during tumor boards and how they implement new treatments. He also gave insight into what he is currently working on and his biggest takeaway from The American Journal of Managed Care®’s Institute for Value-Based Medicine® held in Nashville, TN on August 17, 2023, where he was co-chair.” View Video
Press Releases
Proposed Drug Pricing Policy Would Save Medicare Between $1 Billion and $2.1 Billion Annually
(9/5, ISPOR Press Release) “Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report that identifies expensive Medicare Part B drugs with low added therapeutic benefit and models a reimbursement policy for them based on domestic reference pricing. The article, ‘Incorporating Added Therapeutic Benefit and Domestic Reference Pricing into Medicare Payment for Expensive Part B Drugs,’ was published in the September 2023 issue of Value in Health.” Full
Journals
Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs
Kelly E. Anderson, PhD, et al.
September 2023, Value in Health
Target Trial Emulation with Multi-State Model Analysis to Assess Treatment Effectiveness Using Clinical COVID-19 Data
Oksana Martinuka, et al.
September 2, 2023, BMC Medical Research Methodology
BMC Medical Research Methodology
Comparative Effectiveness and Safety of 36 Therapies or Interventions for Pregnancy Outcomes with Recurrent Implantation Failure: A Systematic Review and Network Meta-Analysis
Yunan He, et al.
September 4, 2023, Journal of Assisted Reproduction and Genetics